{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:57:52Z","timestamp":1777521472965,"version":"3.51.4"},"reference-count":82,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T00:00:00Z","timestamp":1606348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100023447","name":"CHU Sainte-Justine Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100023447","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Lenval Foundation"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Can J Psychiatry"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The potential metabolic adverse effects of second-generation antipsychotics (SGA) need to be monitored. The Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics (CAMESA) offers guidelines for this purpose. We aimed to evaluate the long-term rates of youths receiving monitoring in mental health clinics and document the factors that may influence them.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method:<\/jats:title>\n                    <jats:p>The charts of 180 patients (13.3 \u00b1 3.1 years, 54.4% males) receiving SGA treatment for the first time between January 2016 and June 2018 were reviewed. Monitoring was divided into baseline and 1- to 6-month and 9- to 24-month periods. Population under study was stratified into children (4 to 12 years) and adolescents (13 to 18 years). Sociodemographic characteristics, psychiatric diagnosis and comorbidities, prescribed SGAs and comedications, anthropometric measures (AM), blood pressure (BP), blood tests (BT), electrocardiogram, and the psychiatrist\u2019s years of practice were collected. Cross tables were used to present the monitoring rates. Categories were compared by covariate analysis. Rates of patients monitored across categories were compared using Fisher exact test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Monitoring rates for AM, BT, and BP were 55%, 47.8%, and 46.7% at baseline; 50%, 41.7%, and 45.2% at 1 to 6 months; and 47.2%, 41.5%, and 40.6% at 9 to 24 months, respectively. Higher monitoring rates were significantly associated with adolescent status (baseline, 1 to 6 months), a diagnosis of psychotic and\/or affective disorder (baseline, 1 to 6 months, 9 to 24 months), having \u22641 psychiatric comorbidities (1 to 6 months), high SGA dose (baseline, 1 to 6 months), and clinician\u2019s experience (baseline, 9 to 24 months). Significantly lower monitoring rates were associated with the psychostimulant\/atomoxetine comedication (baseline, 1 to 6 months, 9 to 24 months).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Five years after publication of the CAMESA guidelines, metabolic monitoring is conducted for less than half of patients. In our sample, age, diagnostic category, psychiatric comorbidities, SGA dose, clinician\u2019s experience, and comedications influenced the monitoring rates. Major progress still needs to be made before reaching a satisfactory level of monitoring.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/0706743720974847","type":"journal-article","created":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T02:12:08Z","timestamp":1606443128000},"page":"645-656","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Long-Term Metabolic Monitoring of Youths Treated with Second-Generation Antipsychotics 5 Years after Publication of the CAMESA Guidelines Are We Making Progress? Surveillance M\u00e9tabolique \u00e0 Long Terme des Jeunes Trait\u00e9s par Antipsychotiques de Deuxi\u00e8me G\u00e9n\u00e9ration, Cinq ans Apr\u00e8s la publication des Lignes Directrices Camesa: Faisons-Nous des Progr\u00e8s?"],"prefix":"10.1177","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1348-6316","authenticated-orcid":false,"given":"Sarra","family":"Jazi","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Addictology, University of Montreal, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leila","family":"Ben-Amor","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Addictology, University of Montreal, Montreal, Quebec, Canada"},{"name":"Department of Child and Adolescents Psychiatry, CHU Sainte-Justine Research Center, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascale","family":"Abadie","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Addictology, University of Montreal, Montreal, Quebec, Canada"},{"name":"Child and Adolescents Psychiatry Division, Department of Psychiatry, Rivi\u00e8re-des-Prairies Mental Health Hospital, CIUSSS-NIM, Montreal, Quebec, Canada"},{"name":"CIUSSS-NIM Research Center, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Line","family":"Menard","sequence":"additional","affiliation":[{"name":"Children\u2019s Hospital of Nice, University Department of Child and Adolescent Psychiatry, C\u00f4te d\u2019Azur University, Nice, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Choquette","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, University of Montreal, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claude","family":"Berthiaume","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Addictology, University of Montreal, Montreal, Quebec, Canada"},{"name":"CIUSSS-NIM Research Center, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5668-5422","authenticated-orcid":false,"given":"Laurent","family":"Mottron","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Addictology, University of Montreal, Montreal, Quebec, Canada"},{"name":"Child and Adolescents Psychiatry Division, Department of Psychiatry, Rivi\u00e8re-des-Prairies Mental Health Hospital, CIUSSS-NIM, Montreal, Quebec, Canada"},{"name":"CIUSSS-NIM Research Center, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Drigissa","family":"Ilies","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Addictology, University of Montreal, Montreal, Quebec, Canada"},{"name":"Child and Adolescents Psychiatry Division, Department of Psychiatry, Rivi\u00e8re-des-Prairies Mental Health Hospital, CIUSSS-NIM, Montreal, Quebec, Canada"},{"name":"CIUSSS-NIM Research Center, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,11,26]]},"reference":[{"key":"bibr1-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2017.07.001"},{"key":"bibr2-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1177\/0706743716649190"},{"key":"bibr3-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2019.0018"},{"key":"bibr4-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2010.0145"},{"key":"bibr5-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1177\/070674371205701202"},{"key":"bibr6-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1186\/s13034-017-0192-1"},{"key":"bibr7-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1177\/070674371305800608"},{"key":"bibr8-0706743720974847","volume-title":"Prescription drug list","author":"Government of Canada","year":"2018"},{"issue":"3","key":"bibr9-0706743720974847","first-page":"196","volume":"47","author":"Valiquette JR","year":"2014","journal-title":"Pharmactuel"},{"key":"bibr10-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1177\/070674371205700109"},{"key":"bibr11-0706743720974847","doi-asserted-by":"publisher","DOI":"10.2174\/1381612821666150619092903"},{"key":"bibr12-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-018-0626-4"},{"key":"bibr13-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1002\/eat.22059"},{"key":"bibr14-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2010.07.002"},{"key":"bibr15-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2010.09.011"},{"key":"bibr16-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2011.156"},{"key":"bibr17-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1007\/s00787-013-0399-5"},{"key":"bibr18-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1007\/s40501-013-0007-9"},{"key":"bibr19-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0117166"},{"key":"bibr20-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1186\/s13052-016-0259-2"},{"key":"bibr21-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1002\/j.2051-5545.2011.tb00036.x"},{"key":"bibr22-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1016\/j.childyouth.2016.05.019"},{"key":"bibr23-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2016.0171"},{"key":"bibr24-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2011.2"},{"key":"bibr25-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1176\/ps.2006.57.7.1045a"},{"key":"bibr26-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1177\/070674371205700107"},{"key":"bibr27-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2010.0011"},{"key":"bibr28-0706743720974847","doi-asserted-by":"crossref","unstructured":"American Diabetes Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2): 596\u2013601.","DOI":"10.2337\/diacare.27.2.596"},{"key":"bibr29-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116645254"},{"key":"bibr30-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1080\/13651500510018310"},{"key":"bibr31-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1093\/pch\/16.9.581"},{"key":"bibr32-0706743720974847","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2009.tb02344.x"},{"key":"bibr33-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1177\/1078390317752444"},{"issue":"4","key":"bibr34-0706743720974847","first-page":"292","volume":"18","author":"Honey BL","year":"2013","journal-title":"J Pediatr Pharmacol Ther"},{"key":"bibr35-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1177\/0706743718779950"},{"key":"bibr36-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2014-0828"},{"key":"bibr37-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-016-0209-x"},{"key":"bibr38-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1177\/070674371205700504"},{"key":"bibr39-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1177\/0706743717751693"},{"key":"bibr40-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2018.0167"},{"key":"bibr41-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1177\/0706743717718166"},{"key":"bibr42-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1177\/070674371506001005"},{"key":"bibr43-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2013.2053"},{"key":"bibr44-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.979150"},{"key":"bibr45-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2015.2923"},{"key":"bibr46-0706743720974847","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200721110-00004"},{"key":"bibr47-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1001\/archpediatrics.2010.48"},{"key":"bibr48-0706743720974847","doi-asserted-by":"publisher","DOI":"10.9740\/mhc.2017.01.001"},{"key":"bibr49-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000000853"},{"key":"bibr50-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2014.0156"},{"issue":"3","key":"bibr51-0706743720974847","first-page":"137","volume":"9","author":"Ghate SR","year":"2012","journal-title":"Mental Health Fam Med"},{"key":"bibr52-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-9-80"},{"key":"bibr53-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2008.08030383"},{"key":"bibr54-0706743720974847","unstructured":"Pharmacists CoPaN. Psychiatric Pharmacy Essentials: Antipsychotic Dose Equivalents, https:\/\/cpnp.org\/guideline\/essentials\/antipsychotic-dose-equivalents."},{"key":"bibr55-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1097\/01.chi.0000220851.94392.30"},{"key":"bibr56-0706743720974847","unstructured":"Canadian ADHD. Resource alliance (CADDRA). Canadian ADHD Practice Guidelines. CADDRA.2018."},{"key":"bibr57-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61516-X"},{"key":"bibr58-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20204"},{"key":"bibr59-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000000190"},{"key":"bibr60-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2018.33"},{"key":"bibr61-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1549"},{"key":"bibr62-0706743720974847","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2015.21.9.769"},{"key":"bibr63-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201400222"},{"key":"bibr64-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2017.0034"},{"key":"bibr65-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1097\/chi.0b013e31815b5cb1"},{"key":"bibr66-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3182549259"},{"key":"bibr67-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201900108"},{"key":"bibr68-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1111\/inm.12417"},{"key":"bibr69-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0132891"},{"key":"bibr70-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1089\/met.2010.0127"},{"key":"bibr71-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1097\/01.pra.0000450319.21859.6d"},{"key":"bibr72-0706743720974847","doi-asserted-by":"crossref","unstructured":"Walkup J, Bernet W, Bukstein O, et al. Practice parameter for the use of atypical antipsychotic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry. 2009;48(9):961\u2013973.","DOI":"10.1097\/CHI.0b013e3181ae0a08"},{"key":"bibr73-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.1760501"},{"key":"bibr74-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2007.12.233"},{"key":"bibr75-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1177\/1362361314531341"},{"issue":"2","key":"bibr76-0706743720974847","first-page":"134","volume":"20","author":"Ronsley R","year":"2011","journal-title":"J Can Acad Child Adolesc Psychiatry"},{"key":"bibr77-0706743720974847","unstructured":"Lambert C, Panagiotopoulos C, Davidson J, Goldman RD, et al. Second-generation antipsychotics in children; Risks and monitoring needs. Canadian family physician Medecin de Famille Canadien. 2018;64(9):660\u2013662"},{"key":"bibr78-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1186\/1753-2000-5-36"},{"issue":"9","key":"bibr79-0706743720974847","first-page":"CD008559","author":"Loy JH","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr80-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1089\/1044546041649020"},{"key":"bibr81-0706743720974847","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2008.007"},{"key":"bibr82-0706743720974847","doi-asserted-by":"publisher","DOI":"10.4324\/9780203771587"}],"container-title":["The Canadian Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0706743720974847","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0706743720974847","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0706743720974847","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:14:33Z","timestamp":1777392873000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0706743720974847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,26]]},"references-count":82,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1177\/0706743720974847"],"URL":"https:\/\/doi.org\/10.1177\/0706743720974847","relation":{},"ISSN":["0706-7437","1497-0015"],"issn-type":[{"value":"0706-7437","type":"print"},{"value":"1497-0015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,26]]}}}